Roche Canada crowdsources COVID-19 ideas in new quick-turn innovation challenge

Roche Canada's innovation challenge for COVID-19 health solutions looks to the public for ideas. (Roche)

Roche Canada is looking for a few good ideas to fight COVID-19, and it needs them soon.

The Swiss drugmaker recently launched a Canada-specific innovation challenge, asking for entries by April 10 in a contest that promises up to $100,000 in winnings to fund development.

The Roche Canada COVID-19 Innovation Challenge hopes to uncover any and all ideas that advance the fight against the novel coronavirus, but it does offer suggestions. How to address health system capacities, enhance real-time information-sharing, and manage remote and rural populations, for three. The contest is open only to legal residents of Canada.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: Incyte debuts innovation award to crowdsource ideas for graft-versus-host patients

“We are hoping to get a broad range of interest from all facets of society, including science-based experts such as biologists, data scientists, and healthcare providers, as well as entrepreneurs and technology developers, students, patients, and anyone with an innovative mind and wants to make a difference,” said a Roche spokesperson in an email.  

While innovation challenges by pharma companies have proliferated over the past few years in specific diseases and technologies, the Roche Canada contest is one of the first to crowdsource for COVID-19 ideas.

Entries will be evaluated on five equality weighted criteria: clarity, design, innovativeness, impact and outcome, and feasibility and applicability. A Roche steering committee will choose and notify winners by April 15 and grant funding up to $50,000 for individual winners and $100,000 for team submissions.

RELATED: Celgene, Lyfebulb put patient spin on MS innovation challenge

“We are establishing this initiative in the hope that it can foster much needed solutions and create opportunities for people to get involved," Michael Duong, head of personalized healthcare at Roche Canada, said in a news release. "Every Canadian is touched by this situation and it's going to take the whole community coming together to get through it.”

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.